Tristate CACS Organization

Fanwen Zeng has served as a board member for Tri-State Chinese American Chemical Society (CACS) since 2007 and is the president-elect in 2011. He obtained his Ph.D. in chemistry from the University of Illinois, Urbana-Champaign and was a postdoctoral fellow at the University of California, Berkeley. Since 1999, he has worked for The Dow Chemical Company (formerly, Rohm and Haas Company) as a material chemist in Spring House, Pennsylvania. He has led commercializing a variety of products to serve markets including Plastics Additives, Coatings, Consumer care and Microbial Control. He has been a member of American Chemical Society (ACS), Society of Cosmetic Chemist (SCC), Controlled Release Society (CRS). He also serves as a committee member of CRS’s Consumer and Diversified Products Division. He is also serving as a co-chair of Asia Diversity Network (ADN) of the Dow Chemical Company.

Fangbiao Li has served as a board member for Tri State Chinese American Chemical Society (Tris CACS) since 2007. As the vendor show director of Tris CACS, he successfully started vendor show program during annual symposium for the past three years. His academic experience includes a PhD degree in Chemistry from UCLA and postdoctoral research in Chemistry at Princeton University. Currently he works as a Section Leader in DMPK department of Merck Research Laboratory. He leads a team of scientists to provide PK support for drug discovery projects. He is actively involved in scientific communities and he is also serving on the board of NJACS Mass Spectrometry Discussion Group.

Duxi Zhang has been involved in Tri-state CACS planning activities since 2006 and was elected president in 2009. He holds a PhD degree in Analytical Chemistry from Purdue University and a MS degree in organic analysis from Shandong University. He works as a Senior Research Investigator in the Bioanalytical Sciences department within Bristol‑Myers Squibb R&D in its Princeton research facility. During his time in BMS, he led the bioanalysis support for NDA approval of entecavir (BaracludeÔ), a novel treatment for hepatitis B. He currently leads a team of scientists supporting BMS development projects in infectious disease, oncology, cardiovascular and neuroscience areas. He is a member of ACS, ASMS, and AAPS and a regular reviewer of Journal of Chromatography B. Outside his work, he is actively involved in local scientific communities. He served on the board of NJACS Mass Spectrometry Discussion Group from 2003 to 2007 and was the Chair for 2007. In his spare time, he also coaches kids soccer and enjoys playing volleyball.